Agomab Therapeutics NV(AGMB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AGMB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Agomab Therapeutics NV (AGMB), a Healthcare sector company. AGMB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Top institutional holders of AGMB by reported 13-F value include EQT Fund Management S.a r.l., Sanofi, Cormorant Asset Management,, based on the most recent SEC filings. AGMB trades on the Nasdaq exchange and files with the SEC under CIK 2020932. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Agomab Therapeutics NV directly from SEC EDGAR.
AI Insight: AGMB Financial Trends
No quarterly financial data available for Agomab Therapeutics NV to assess financial trends or performance metrics.
• Insufficient financial data to identify revenue, profitability, or cash flow trends.
⚠ Lack of reported quarterly financials limits visibility into operational performance and cash burn rate.
AI Insight: AGMB Ratio Trends
No financial ratio data available to assess Agomab Therapeutics' operational trends or performance metrics.
• Insufficient financial data to identify meaningful operational trends.
⚠ Lack of available ratio data limits visibility into company's financial health and performance trajectory.
Get alerted when AGMB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Agomab Therapeutics NV including:
Top Institutional Holders of AGMB
EQT Fund Management S.a r.l.
$53.9M5,141,992 shSanofi
$29.2M2,783,096 shCormorant Asset Management, LP
$25.9M2,465,348 shTCG Crossover Management, LLC
$21.5M2,053,233 shFEDERATED HERMES, INC.
$17.0M1,618,000 shCasdin Capital, LLC
$16.3M1,550,000 shAndera Partners
$16.1M1,538,702 shFMR LLC
$15.3M1,458,677 shNantahala Capital Management, LLC
$12.9M1,200,000 shabrdn plc
$7.4M707,656 sh
| Fund | Value | Shares |
|---|---|---|
| EQT Fund Management S.a r.l. | $53.9M | 5,141,992 |
| Sanofi | $29.2M | 2,783,096 |
| Cormorant Asset Management, LP | $25.9M | 2,465,348 |
| TCG Crossover Management, LLC | $21.5M | 2,053,233 |
| FEDERATED HERMES, INC. | $17.0M | 1,618,000 |
| Casdin Capital, LLC | $16.3M | 1,550,000 |
| Andera Partners | $16.1M | 1,538,702 |
| FMR LLC | $15.3M | 1,458,677 |
| Nantahala Capital Management, LLC | $12.9M | 1,200,000 |
| abrdn plc | $7.4M | 707,656 |
More Healthcare Companies
View all Healthcare →Put AGMB on your watchlist
Track score changes the day Agomab Therapeutics NV files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AGMB a good stock to buy?
13F Pro's AI-powered analysis of Agomab Therapeutics NV (AGMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AGMB are available on the AGMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AGMB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AGMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Agomab Therapeutics NV's investment landscape.